Cancer Communications
indexed by SCI
BMC

[ Special series on Breast Cancer ]
doi: 10.1186/s40880-016-0095-1
Accelerated partial breast irradiation: advances and controversies
Mani Akhtari and Bin S. Teh
Department of Radiation Oncology, Houston Methodist Hospital, Cancer Center and Research Institute, Weil Cornell Medical College
[Abstract] The management of localized breast cancer has changed dramatically over the past three to four decades. Breast-conserving therapy, which involved lumpectomy followed by adjuvant irradiation, is now widely considered the standard of care in women with early-stage breast cancer. Accelerated partial breast irradiation (APBI), which involves focal irradiation of the lumpectomy cavity over a short period of time, has developed over the past two decades as an alternative to whole breast irradiation (WBI). Multiple APBI modalities have been developed including brachytherapy, external beam irradiation, and intraoperative irradiation. These new techniques have provided early-stage breast cancer patients with shorter treatment duration and more focused irradiation, delivering very high biological doses to the region at a high risk of failures over a much shorter treatment course as compared with conventional radiotherapy. However, the advantages of APBI over conventional radiotherapy are controversial, including a higher risk of complications reported in retrospective literature and shorter follow-up duration in the intraoperative APBI trials. Nevertheless, APBI presents a valuable alternative to WBI for a selected population of women with early-stage breast cancer.
Chinese Journal of Cancer 2016, Volume: 35, Issue 4
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)

[Google Scholar]


[ More articles of the special series on Breast Cancer ]


Cite this article

Mani Akhtari and Bin S. Teh. Accelerated partial breast irradiation: advances and controversies. Chin J Cancer. 2016, 35:31. doi:10.1186/s40880-016-0095-1


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China